US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Merger strengthens Toleranzia’s prospects

Toleranzia and its major shareholder Flerie are proposing a merger, with Toleranzia’s assets living on in an unlisted environment. The merger will improve the ability to finance the continued development of Toleranzia’s drug projects while providing shareholders with a more risk-balanced exposure to Flerie’s broad portfolio. BioStock contacted Charlotte Fribert, CEO of Toleranzia, and Ted Fjällman, CEO of Flerie, to learn more about the deal.Read the full article at biostock.se : https://www.biostock.se/en/2025/03/merger-strengthens-toleranzias-prospects/

BioStock: Toleranzia advances its projects despite challenges linked to Covid-19

Toleranzia, that develops potentially curative treatments for severe autoimmune diseases, is, like many other companies, affected by the Covid-19 pandemic. The company recently announced that the planned clinical trial of its drug candidate TOL2 will be postponed until the second half of 2023, due to the fact that the unabated global need for Covid-19 vaccine in the world is causing an extensive shortage of materials needed to purify Toleranzia’s drug candidate. BioStock contacted Toleranzia’s CEO Charlotte Fribert to find out how the company is affected by the delay.Read the full interview

BioStock: Toleranzia carries out directed issue of up to 42 MSEK

Biotech company Toleranzia announced last night that it has decided to carry out a directed share issue to Flerie Invest and Nordic Tender, subject to approval at an extraordinary general meeting. At the same time, Flerie Invest’s founder Thomas Eldered is proposed for election to the company’s board. The issue is expected to raise up to approximately 42 MSEK, which will be used to accelerate the development of Toleranzia’s main candidate TOL2 – a potential new treatment for the serious nerve and muscle disease myasthenia gravis.Read the full interview with CEO Charlotte Fribert at biostock.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe